WO2024258856A1 - Formes posologiques orales solides d'agents de dégradation des récepteurs des œstrogènes - Google Patents

Formes posologiques orales solides d'agents de dégradation des récepteurs des œstrogènes Download PDF

Info

Publication number
WO2024258856A1
WO2024258856A1 PCT/US2024/033417 US2024033417W WO2024258856A1 WO 2024258856 A1 WO2024258856 A1 WO 2024258856A1 US 2024033417 W US2024033417 W US 2024033417W WO 2024258856 A1 WO2024258856 A1 WO 2024258856A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
dosage form
tablet
oral dosage
solid oral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/033417
Other languages
English (en)
Inventor
III Royal J. HASKELL
Joseph P. Reo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arvinas Operations Inc
Original Assignee
Arvinas Operations Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arvinas Operations Inc filed Critical Arvinas Operations Inc
Priority to KR1020267000497A priority Critical patent/KR20260022394A/ko
Priority to CN202480038499.7A priority patent/CN121311218A/zh
Priority to AU2024303588A priority patent/AU2024303588A1/en
Publication of WO2024258856A1 publication Critical patent/WO2024258856A1/fr
Priority to IL325099A priority patent/IL325099A/en
Priority to MX2025014795A priority patent/MX2025014795A/es
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • Certain bifunctional compounds target specific cellular proteins for degradation via the ubiquitin-proteasome system.
  • proteolysis targeting chimeric compounds i.e., “PROTAC® protein degraders”
  • ER estrogen receptor
  • Such bifunctional molecules exhibit a range of pharmacological activities consistent with the degradation of the ER including, but not limited to, treatment or amelioration of a disease condition such as cancer (e.g., breast cancer, uterine cancer, ovarian cancer, prostate cancer, endometrial cancer), or endometriosis.
  • a bifunctional molecule of particular interest is (5)-3-(5-(4-((l-(4-((lR,25)-6-hydroxy-2-phenyl- 1 ,2,3 ,4-tetrahydronaphthalen- 1 -yl)pheny l)piperidin-4-yl)methyl)piperazin- 1 -yl)- 1 -oxoisoindolin- 2-yl)piperidine-2, 6-dione or (35)-3-[l,3-dihydro-l-oxo-5-[4-[[l-[4-[(lR,25)-l,2,3,4-tetrahydro- 6-hydroxy-2-phenyl-l-naphthalenylphenyl]-4-piperidinyl]methyl]-l-piperazinyl]-27/-isoindol-2- yl]-2,6-piperidinedione (referred to herein as “Compound A” or “Cpd A”), which
  • Compound A is under development as a PROTAC® protein degrader that targets ER for the potential treatment of breast cancer and has been shown to be a useful modulator of targeted protein ubiquitination and degradation via the ubiquitin-proteasome pathway.
  • dosage forms of Compound A including those suitable for oral administration.
  • Such dosage forms may have certain advantages (e.g., increased oral bioavailability) and may be useful for safe, effective and/or convenient administration of Compound A to patients for, e.g., treating cancers (e.g., breast cancer).
  • solid oral dosage forms e.g., tablets
  • solid oral dosage forms comprising Compound A: or a pharmaceutically acceptable salt thereof.
  • solid oral dosage forms comprising Compound A, or a pharmaceutically acceptable salt thereof, a polymer, and a surfactant.
  • the amount of Compound A in the solid oral dosage form is about 5 mg to about 500 mg.
  • the solid oral dosage form is a tablet, a sachet, or a capsule.
  • the solid oral dosage form further comprises one or more excipients selected from fillers, disintegrants, glidants, and lubricants.
  • excipients include, but are not limited to, microcrystalline cellulose, silicified microcrystalline cellulose, lactose monohydrate, mannitol, sorbitol, xylitol, hydroxypropyl methylcellulose, hydroxypropyl cellulose, pullulan, fast-dissolving carbohydrates, and combinations thereof.
  • Exemplary disintegrants include, but are not limited to, sodium starch glycolate, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, croscarmellose sodium, crospovidone, chitosan, agar, alginic acid, calcium alginate, methyl cellulose, microcrystalline cellulose, powdered cellulose, lower alkyl substituted hydroxypropyl cellulose, hydroxylpropyl starch, low-substituted hydroxypropylcellulose, polacrilin potassium, starch, pregelatinized starch, sodium alginate, polacrilin potassium, povidone, and combinations thereof.
  • Exemplary glidants include, but are not limited to, silicon dioxide, colloidal silicon dioxide, calcium silicate, magnesium silicate, magnesium trisilicate, talc, starch, and combinations thereof.
  • Exemplary lubricants include, but are not limited to, magnesium stearate, calcium stearate, glyceryl monostearate, glyceryl behenate, glyceryl palmitostearate, hexagonal boron nitride, hydrogenated vegetable oil, light mineral oil, mineral oil, polyethylene glycol, poloxamer, sodium benzoate, sodium lauryl sulfate, sodium stearyl fumarate, stearic acid, talc, zinc stearate, and combinations thereof.
  • the solid oral dosage form is a tablet. In embodiments, the tablet is film coated.
  • the solid oral dosage form (e.g., the tablet) comprises: about 15% w/w to about 50% w/w of Compound A; about 10% w/w to about 40% w/w of hydroxypropyl methylcellulose; about 0.5% w/w to about 5% w/w of D-a-tocopheryl polyethylene glycol succinate; about 10% w/w to about 40% w/w of microcrystalline cellulose; about 5%w/w to about 15%w/w of lactose monohydrate; about 5%w/w to about 15% w/w of croscarmellose sodium; about 0%w/w to about 5% w/w of silicon dioxide; and about 0%w/w to about 2% w/w of sodium stearyl fumarate.
  • the solid oral dosage form (e.g., the tablet) comprises:
  • the solid oral dosage form (e.g., the tablet) comprises: about 42% w/w of Compound A; about 15% w/w of hydroxypropyl methylcellulose; about 3% w/w of D-a-tocopheryl polyethylene glycol succinate; about 17% w/w of microcrystalline cellulose; about 8.8% w/w of lactose monohydrate; about 12% w/w of croscarmellose sodium; about 1% w/w of silicon dioxide; and about 1.5% w/w of sodium stearyl fumarate.
  • the solid oral dosage form (e.g., the tablet) comprises: about 20% w/w of Compound A; about 28% w/w of hydroxypropyl methylcellulose; about 2.5% w/w of D-a-tocopheryl polyethylene glycol succinate; about 27% w/w of microcrystalline cellulose; about 9% w/w of lactose monohydrate; about 12% w/w of croscarmellose sodium; about 1% w/w of silicon dioxide; and about 1.5% w/w of sodium stearyl fumarate.
  • the solid oral dosage form (e.g., the tablet) comprises an intra-granular portion and an extra-granular portion, and, optionally, a film coating, wherein the intra-granular portion comprises: about 15% to about 50% w/w of Compound A; about 10% to about 40% w/w of hydroxypropyl methylcellulose; about 0.5% to about 5% w/w of D-a-tocopheryl polyethylene glycol succinate; about 5% to about 10% w/w of microcrystalline cellulose; about 5% to about 10% w/w of lactose monohydrate; about 1% to about 10% w/w of croscarmellose sodium; about 0% to about 5% w/w of silicon dioxide; and about 0% to about 2% w/w of sodium stearyl fumarate, and wherein the extra- granular portion comprises: about 5 to about 25% w/w of microcrystalline cellulose; about 0% to about 10% w/w of croscarmellose sodium; and about 0% to about
  • the solid oral dosage form (e.g., the tablet) comprises an intra-granular portion and an extra-granular portion, and optionally, a film coating
  • the intra-granular portion comprises: about 42% w/w of Compound A; about 14% w/w hydroxypropyl methylcellulose; about 3% w/w d-a-tocopheryl polyethylene glycol succinate; about 9% w/w microcrystalline cellulose; about 9% w/w lactose monohydrate; about 6% w/w croscarmellose sodium; about 1% w/w silicon dioxide; and about 0.75% w/w sodium stearyl fumarate; and wherein the extra- granular portion comprises: about 8% w/w microcrystalline cellulose; about 6% w/w croscarmellose sodium; and about 0.75% w/w sodium stearyl fumarate; wherein weight percentages are relative to the total uncoated tablet weight.
  • the solid oral dosage form (e.g., the tablet) comprises an intra-granular portion and an extra-granular portion, and, optionally, a film coating, wherein the intra-granular portion comprises: about 20% w/w of Compound A; about 28% w/w of hydroxypropyl methylcellulose; about 2.5% w/w of D-a-tocopheryl polyethylene glycol succinate; about 8% w/w of microcrystalline cellulose; about 9% w/w of lactose monohydrate; about 6% w/w of croscarmellose sodium; about 1% w/w of silicon dioxide; and about 0.75% w/w of sodium stearyl fumarate, and wherein the extra- granular portion comprises: about 18% w/w of microcrystalline cellulose; about 6% w/w of croscarmellose sodium; and about 0.75% w/w of sodium stearyl fumarate; wherein weight percentages are relative to the total uncoated tablet weight.
  • the solid oral dosage form (e.g., the tablet) comprises about 5 mg, about 10 mg, about 15 mg, about 10 mg, about 25 mg, about 30 mg, about 50 mg, about 75 mg, about 100 mg, about 125 mg, about 150 mg, about 200 mg, about 250 mg, or about 300 mg of Compound A.
  • the solid oral dosage form comprises about 200 mg of Compound A.
  • the solid oral dosage form comprises about 100 mg of Compound A.
  • the solid oral dosage form comprises about 250 mg of Compound A.
  • the solid oral dosage form Comprises about 50 mg of Compound A.
  • mixtures comprising Compound A, or a pharmaceutically acceptable salt thereof, a polymer, and a surfactant.
  • sprayed dried dispersions comprising Compound A, or a pharmaceutically acceptable salt thereof, a polymer, and a surfactant.
  • Methods of making the spray dried dispersions disclosed herein are also provided. Such methods comprise:
  • the solvent is a mixture of dichloromethane and methanol. In embodiments the solvent is a mixture of about 90:10 (w/w) to about 70:30 (w/w) dichloromethane:methanol. In embodiments, the solvent is a mixture of about 80:20 (w/w) dichloromethane:methanol. In embodiments, the solvent is a mixture of about 85: 15 (w/w) di chloromethane: methanol.
  • removing residual solvent comprises drying (e.g., agitated conical drying).
  • FIG. 1 shows the results of pharmacokinetic (PK) studies in fasted female dogs orally administered aqueous suspensions of Compound A, as described in Example 2.
  • PK pharmacokinetic
  • FIGs. 2A-2D show the results of PK studies in fasted female dogs orally administered tablets of Compound A, as described in Example 3.
  • FIGs. 3A-3D show the results of PK studies in fed female dogs orally administered tablets of Compound A, as described in Example 3. DETAILED DESCRIPTION
  • an excipient includes one or more excipients.
  • the term “about” when used to modify a numerically defined parameter means that the parameter may vary by as much as 10% below or above the stated numerical value for that parameter.
  • a dose of about 5 mg means 5 mg ⁇ 10%, i.e., it may vary from 4.5 mg to 5.5 mg.
  • agents including, but not limited to, “agent,” “composition,” “compound,” “drug,” and “therapeutic agent” may be used interchangeably to refer to compounds included in the methods and uses of the present disclosure.
  • amorphous form refers to solids of disordered arrangements of molecules and that do not possess a distinguishable crystal lattice.
  • Compound A has the structure: Compound A is a Biopharmaceutics Classification System Class IV compound (low solubility/low permeability). Compound A may inter convert to its epimer, Compound B:
  • preclinical data indicates that the exposure of Compound B is limited compared to Compound A ( ⁇ 26%).
  • Evidence indicates that Compound B does not degrade the ER; however, Compound B shows similar antagonism of ER dependent transcription compared to Compound A.
  • compositions described herein relate to the pharmaceutically acceptable salts of the compounds described herein.
  • Pharmaceutically acceptable salts of the compounds described herein include the acid addition and base addition salts thereof.
  • Suitable acid addition salts are formed from acids which form nontoxic salts.
  • suitable acid addition salts i.e., salts containing pharmacologically acceptable anions, include, but are not limited to, the acetate, acid citrate, adipate, aspartate, benzoate, besylate, bicarbonate/carbonate, bisulphate/sulphate, bitartrate, borate, camsylate, citrate, cyclamate, edisylate, esylate, ethanesulfonate, formate, fumarate, gluceptate, gluconate, glucuronate, hexafluorophosphate, hibenzate, hydrochloride/chloride, hydrobromide/bromide, hydroiodide/iodide, isethionate, lactate, malate, maleate, malonate, mesylate, methanes
  • Suitable base addition salts are formed from bases that form non-toxic salts.
  • suitable base salts include the aluminum, arginine, benzathine, calcium, choline, diethylamine, diolamine, glycine, lysine, magnesium, meglumine, olamine, potassium, sodium, tromethamine, and zinc salts.
  • the compounds described herein that are basic in nature can form a wide variety of salts with various inorganic and organic acids.
  • the acids that may be used to prepare pharmaceutically acceptable acid addition salts of such basic compounds described herein are those that form nontoxic acid addition salts, e.g., salts containing pharmacologically acceptable anions, such as the hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, acid citrate, tartrate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucuronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pam
  • the chemical bases that may be used as reagents to prepare pharmaceutically acceptable base salts of those compounds of the compounds described herein that are acidic in nature are those that form non-toxic base salts with such compounds.
  • Such non-toxic base salts include, but are not limited to, those derived from such pharmacologically acceptable cations such as alkali metal cations (e.g., potassium and sodium) and alkaline earth metal cations (e.g., calcium and magnesium), ammonium or water-soluble amine addition salts such as N-methylglucamine- (meglumine), and the lower alkanolammonium and other base salts of pharmaceutically acceptable organic amines.
  • Hemisalts of acids and bases may also be formed, for example, hemisulphate, and hemicalcium salts.
  • suitable salts see Handbook of Pharmaceutical Salts: Properties, Selection, and Use by Stahl and Wermuth (Wiley-VCH, 2002). Methods for making pharmaceutically acceptable salts of compounds described herein are known to one of skill in the art.
  • the terms, “subject” and “patient,” are used interchangeably, to refer to any animal, including mammals.
  • Mammals according to the disclosure include canine, feline, bovine, caprine, equine, ovine, porcine, rodents, lagomorphs, primates, humans, and the like, and encompass mammals in utero.
  • humans are suitable subjects. Human subjects may be of any gender and at any stage of development.
  • API Active pharmaceutical Ingredients
  • Any active ingredient is a substance that directly affects the ailment or targets the disease and is intended to use in manufacturing is known as API. These substances are considered crucial as they provide pharmacological activity or direct effects in the diagnosis, cure, treatment, prevention, or affect the body’s structure.
  • Oral dosage form refers to a pharmaceutical drug product that contains a specified amount (dose) of a compound of the disclosure as the API, or a pharmaceutically acceptable salt and/or solvate thereof, and inactive components (excipients), formulated into a particular configuration that is suitable for oral administration, such as an oral tablet, liquid, or capsule.
  • the oral dosage form comprises a tablet.
  • the oral dosage form comprises a tablet that can be scored.
  • the oral dosage form comprises a sublingual tablet.
  • Oral administration refers to enteral, buccal, sublabial, or sublingual medications in the form of tablets, capsules, syrups, powders, granules, pastilles, solutions, tinctures, elixirs, emulsions, hydrogels, teas, films, disintegrating tablets, mouthwashes, and others.
  • Drug dissolution represents a critical factor affecting the rate of systemic absorption.
  • a variety of in vitro methods have been developed for assessing the dissolution properties of pharmaceutical formulations, and dissolution testing is sometimes used as a surrogate for the direct evaluation of drug bioavailability. See, e.g, Emmanuel etal., Pharmaceutics (2010), 2:351-63, and references cited therein.
  • Dissolution testing measures the percentage of API that has been released from a drug product (e.g., tablet) and dissolved in a dissolution medium under controlled testing conditions over a defined period of time. To maintain sink conditions, saturation solubility of the drug in the dissolution media should be at least three times the drug concentration. For low solubility compounds, dissolution may sometimes be determined under non-sink conditions.
  • Dissolution is affected by the properties of the API (e.g., particle size, crystal form, bulk density), the composition of the drug product (e.g., drug loading, excipients), the manufacturing process (e.g., compression forces) and the stability under storage conditions (e.g., temperature, humidity).
  • properties of the API e.g., particle size, crystal form, bulk density
  • the composition of the drug product e.g., drug loading, excipients
  • the manufacturing process e.g., compression forces
  • stability under storage conditions e.g., temperature, humidity
  • a “solid oral dosage form” of the present invention is a pharmaceutically acceptable solid oral dosage form that is safe for oral administration to subjects, where all excipients in the dosage form are pharmaceutically acceptable for use in oral formulations, in other words safe for ingestion.
  • the solid oral dosage form is a tablet.
  • Solid oral dosage forms include, but are not limited to, immediate release tablets and capsules, controlled-release (CR) tablets and capsules, fast-dissolve dosage forms, chewable dosage forms, sachets, etc.
  • the dosage form of the present invention is in the form of a tablet, including monolayer or bilayer tablets.
  • unit dose or “unit dosage” refers to a physically discrete unit that contains a predetermined quantity of active ingredient calculated to produce a desired therapeutic effect.
  • the unit dose or unit dosage may be in the form of a tablet, capsule, sachet, etc. referred to herein as a “unit dosage form.”
  • fasted as used herein is defined as follows: a dosing state which is defined following an overnight fast (wherein 0 caloric intake has occurred) of at least 10 hours. Dosing gavage tubes were flushed with 10 mL water. Food was provided 2 hours post dose. Drinking water may be allowed as desired.
  • fed as used herein is defined as follows: a dosing state which is defined following an overnight fast (wherein 0 caloric intake has occurred) of at least 10 hours. Food was provided 0.5-lh before dosing. Gavage tubes were flushed with 10 mL water. Drinking water may be allowed as desired.
  • dry granulation means the process of blending bulk active product with at least one excipient.
  • the blend is then compressed, or compacted, to form a compressed material or “compact.”
  • This material may be broken apart to form granules by crushing, grinding, or cutting into dry granulated particles.
  • the particles may be further processed. Crushing, grinding, or cutting processes involve an operation that reduces the size of the compressed material such as accomplished by milling or by other operations known to those skilled in the art.
  • % w/w means the weight percentage of the component in respect to the total weight of the composition. It is understood that, when a composition is described in which ranges are provided for multiple components, the total amount of all recited components does not exceed 100%. It is within the ability of a skilled artisan to adjust the amounts within the ranges provided to accomplish this.
  • solid dispersion refers to a solid state that comprises at least two constituents, wherein one constituent is homogenously dispersed substantially evenly throughout the other constituent or constituents. It includes solid or glassy solutions, i.e., the dispersion of the constituents is in such a way that the composition is chemically and physically homogenous in nature.
  • the first constituent is an API
  • the second constituent is a matrix that comprises a polymer, wherein the API is dispersed significantly uniformly within the matrix (the polymer).
  • the API may be present in an amorphous state or in fine crystalline dispersed form. Also, the API may be available as a mixture of amorphous and crystalline forms.
  • a solid dispersion may comprise more than two constituents.
  • two or more APIs may be dispersed into the matrix, and/or the matrix may comprise two or more polymers.
  • solid dispersions may be physically classified as a eutectic mixture, a solid solution, a glass solution, or suspension, an amorphous precipitate in a glassy or crystalline carrier, a complex, a complexed formation or a combination of the different systems.
  • Solid dispersions may be prepared using various techniques known to those skilled in the art, such as by co-dissolving the API and polymer in a solvent then spraydrying, spray-congealing, evaporation, curing or microwaving, blending and direct compression, mechanical admixture at an elevated, but non-melting temperature, wet granulation, extrusion- spheronization, melt fusion, hot melt extrusion, and the like.
  • Compound A may be prepared according to the methods disclosed in US Patent No. 10,647,698, which is incorporated herein in its entirety.
  • mixtures comprising Compound A, a polymer, and a surfactant.
  • the mixture is a dispersion.
  • the mixture is a spray dried dispersion.
  • the polymer is hydroxypropyl methylcellulose (HPMC, also known as hypromellose), a hydroxypropyl methylcellulose derivative, a polyvinylpyrrolidone copolymer, a methacrylic acid copolymer, polyethylene glycol, or a polyethylene glycol derivative.
  • HPMC may further be described by a letter (e.g., E, K) and number (e.g., 3, 5, 15) indicating the viscosity and substitution chemistry of the polymer.
  • Hydroxypropyl methylcellulose derivatives include, e.g., organic acid esters of HPMC.
  • a hydroxypropyl methylcellulose derivative may be selected from the group consisting of, e.g., hydroxypropyl methylcellulose acetate succinate (HPMCAS), hydroxypropyl methylcellulose phthalate (HPMCP), hydroxypropyl methylcellulose succinate (HPMCS), hydroxypropyl methylcellulose trimellitate (HPMCT), hydroxypropyl methylcellulose acetate phthalate (HPMCAP), and hydroxypropyl methylcellulose acetate maleate (HPMCAM).
  • HPMCAS hydroxypropyl methylcellulose acetate succinate
  • HPMCP hydroxypropyl methylcellulose phthalate
  • HPMCS hydroxypropyl methylcellulose succinate
  • HPMCT hydroxypropyl methylcellulose trimellitate
  • HPMCCAP hydroxypropyl methylcellulose acetate phthalate
  • HPCAM hydroxypropyl methylcellulose
  • Polyvinylpyrrolidone copolymer “copolymer of vinylpyrrolidone,” or “PVP copolymer” refers to copolymers comprising vinylpyrrolidone and one or more other monomers, such as acrylic monomers, styrene, vinyl acetate, and the like.
  • Polyvinylpyrrolidone vinyl acetate copolymer and copovidone are exemplary polyvinylpyrrolidone copolymers and are commercially available from numerous sources.
  • the polyvinylpyrrolidone copolymer has an average molecular weight of about 1,000 Daltons to about 1,000,000 Daltons; or of about 1,000 Daltons to about 500,000 Daltons; or of about 1,000 Daltons to about 200,000. In embodiments, the polyvinylpyrrolidone copolymer has an average molecular weight of about 1,000 Daltons to about 150,000 Daltons. In embodiments, the polyvinylpyrrolidone copolymer has an average molecular weight of about 10,000 Daltons to about 150,000 Daltons. In embodiments, the polyvinylpyrrolidone copolymer has an average molecular weight of about 50,000 Daltons to about 150,000 Daltons. In embodiments, the PVP copolymer is a polyvinylpyrrolidone vinyl acetate copolymer.
  • Polyvinylpyrrolidone vinyl acetate copolymer “copolymer of polyvinylpyrrolidone,” “vinyl acetate,” and “PVPVA” refer to a class of copolymers of vinylpyrrolidone and vinyl acetate having varying wt. % ratios of vinylpyrrolidone to vinyl acetate, such as of about 30:70 to about 70:30, including about 30:70, about 35:65, about 50:50, about 60:40, and about 70:30. The wt. % ratios of vinylpyrrolidone to vinyl acetate may result in different properties of the copolymer, including the glass transition temperature.
  • Polyvinylpyrrolidone vinyl acetate copolymer is an exemplary pharmaceutically acceptable polymer and thermoplastic polymer. Polyvinylpyrrolidone vinyl acetate copolymer is commercially available from numerous sources.
  • methacrylic acid copolymer refers to the class of polymeric compounds described by the formula:
  • the methacrylic acid copolymer is a Eudragit® methacrylic acid copolymer.
  • Eudragit® methacrylic acid copolymer is used in its conventional sense to refer to copolymers derived from esters of acrylic and methacrylic acid.
  • Eudragit® polymers may be methacrylic acid copolymers (e.g., functional group being carboxylic acid).
  • the Eudragit® polymer is a methacrylic acid Eudragit® polymer, such as Eudragit® LI 00 or Eudragit® LI 00-55. Eudragit® polymers are commercially available.
  • the surfactant is selected from polyethylene glycol, a polyethylene glycol ester, glycerol esters, and mixtures thereof.
  • the surfactant is a vitamin E ester of polyethylene glycol.
  • the surfactant is D-a-tocopheryl polyethylene glycol succinate (i.e., Vitamin E TPGS).
  • the surfactant is D-a-tocopheryl polyethylene glycol 1000 succinate.
  • the mixture (e.g., the dispersion (e.g., the spray dried dispersion)) comprises Compound A, hydroxypropyl methylcellulose, and D-a-tocopheryl polyethylene glycol succinate.
  • the mixture (e.g., the dispersion (e.g., the spray dried dispersion)) comprises about 20% (w/w) to about 60% (w/w) Compound A. In embodiments, the mixture (e.g., the dispersion (e.g., the spray dried dispersion)) comprises about 30% (w/w) to about 50% (w/w) Compound A. In embodiments, the mixture (e.g., the dispersion (e.g., the spray dried dispersion)) comprises about 35% (w/w) to about 45% (w/w) Compound A.
  • the mixture (e.g., the dispersion (e.g., the spray dried dispersion)) comprises 20% (w/w) to 60% (w/w) Compound A. In embodiments, the mixture (e.g., the dispersion (e.g., the spray dried dispersion)) comprises 30% (w/w) to 50% (w/w) Compound A. In embodiments, the mixture (e.g., the dispersion (e.g., the spray dried dispersion)) comprises 35% (w/w) to 45% (w/w) Compound A.
  • the mixture (e.g., the dispersion (e.g., the spray dried dispersion)) comprises about 20% (w/w), about 25% (w/w), about 30% (w/w), about 35% (w/w), about 36% (w/w), about 37% (w/w), about 38% (w/w), about 39% (w/w), about 40% (w/w), about 41% (w/w), about 42% (w/w), about 43% (w/w), about 44% (w/w), about 45%(w/w), about 50% (w/w), about 55% (w/w), or about 60% (w/w) Compound A.
  • the mixture (e.g., the dispersion (e.g., the spray dried dispersion)) comprises about 50% (w/w) to about 90% (w/w) Compound A. In embodiments, the mixture (e.g., the dispersion (e.g., the spray dried dispersion)) comprises about 60% (w/w) to about 80% (w/w) Compound A. In embodiments, the mixture (e.g., the dispersion (e.g., the spray dried dispersion)) comprises about 65% (w/w) to about 75% (w/w) Compound A.
  • the mixture (e.g., the dispersion (e.g., the spray dried dispersion)) comprises 50% (w/w) and 90% (w/w) Compound A. In embodiments, the mixture (e.g., the dispersion (e.g., the spray dried dispersion)) comprises 60% (w/w) and 80% (w/w) Compound A. In embodiments, the mixture (e.g., the dispersion (e.g., the spray dried dispersion)) comprises 65% (w/w) and 75% (w/w) Compound A.
  • the mixture (e.g., the dispersion (e.g., the spray dried dispersion)) comprises about 50% (w/w), about 55% (w/w), about 60% (w/w), about 65% (w/w), about 66% (w/w), about 67% (w/w), about 68% (w/w), about 69% (w/w), about 70% (w/w), about 71% (w/w), about 72% (w/w), about 73% (w/w), about 74% (w/w), about 75% (w/w), about 80% (w/w), about 85% (w/w), or about 90% (w/w) Compound A.
  • the mixture (e.g., the dispersion (e.g., the spray dried dispersion)) comprises about 35% (w/w) to about 75% (w/w) of a polymer. In embodiments, the mixture (e.g., the dispersion (e.g., the spray dried dispersion)) comprises about 45% (w/w) to about 65 % (w/w) of a polymer. In embodiments, the mixture (e.g., the dispersion (e.g., the spray dried dispersion)) comprises about 40% (w/w) to about 50% (w/w) of a polymer.
  • the mixture (e.g., the dispersion (e.g., the spray dried dispersion)) comprises 35% (w/w) to 75% (w/w) of a polymer. In embodiments, the mixture (e.g., the dispersion (e.g., the spray dried dispersion)) comprises 45% (w/w) to 65 % (w/w) of a polymer. In embodiments, the mixture (e.g., the dispersion (e.g., the spray dried dispersion)) comprises from 40% (w/w) to 50% (w/w) of a polymer.
  • the mixture e.g., the dispersion (e.g, the spray dried dispersion)
  • the mixture comprises about 35% (w/w), about 40% (w/w), about 45% (w/w), about 50% (w/w), about 51% (w/w), about 52% (w/w), about 53% (w/w), about 54% (w/w), about 55% (w/w), about 56% (w/w), about 57% (w/w), about 58% (w/w), about 59% (w/w), about 60% (w/w), about 65% (w/w), about 70% (w/w), or about 75% (w/w) of a polymer.
  • the mixture (e.g., the dispersion (e.g., the spray dried dispersion)) comprises about 10% (w/w) to about 40% (w/w) of a polymer. In embodiments, the mixture (e.g., the dispersion (e.g., the spray dried dispersion)) comprises about 15% (w/w) to about 35% (w/w) of a polymer. In embodiments, the mixture (e.g., the dispersion (e.g., the spray dried dispersion)) comprises about 20% (w/w) to about 30% (w/w) of a polymer.
  • the mixture (e.g., the dispersion (e.g., the spray dried dispersion)) comprises 10% (w/w) to 40% (w/w) of a polymer. In embodiments, the mixture (e.g., the dispersion (e.g., the spray dried dispersion)) comprises 15% (w/w) to 35% (w/w) of a polymer. In embodiments, the mixture (e.g., the dispersion (e.g., the spray dried dispersion)) comprises 20% (w/w) to 30% (w/w) of a polymer.
  • the mixture (e.g., the dispersion (e.g., the spray dried dispersion)) comprises about 10% (w/w), about 15% (w/w), about 20% (w/w), about 21% (w/w), about 22% (w/w), about 23% (w/w), about 24% (w/w), about 25% (w/w), about 26% (w/w), about 27% (w/w), about 28% (w/w), about 29% (w/w), about 30% (w/w), about 35% (w/w), or about 40% (w/w) of a polymer.
  • the mixture (e.g., the dispersion (e.g., the spray dried dispersion)) comprises about 35% (w/w) to about 75% (w/w) of hydroxypropyl methylcellulose. In embodiments, the mixture (e.g., the dispersion (e.g., the spray dried dispersion)) comprises about 45% (w/w) to about 65% (w/w) of hydroxypropyl methylcellulose. In embodiments, the mixture (e.g., the dispersion (e.g., the spray dried dispersion)) comprises about 40% (w/w) to about 50% (w/w) of hydroxypropyl methylcellulose.
  • the mixture (e.g., the dispersion (e.g., the spray dried dispersion)) comprises 35% (w/w) to 75% (w/w) of hydroxypropyl methylcellulose. In embodiments, the mixture (e.g., the dispersion (e.g., the spray dried dispersion)) comprises 45% (w/w) to 65% (w/w) of hydroxypropyl methylcellulose. In embodiments, the mixture (e.g., the dispersion (e.g., the spray dried dispersion)) comprises from 40% (w/w) to 50% (w/w) of hydroxypropyl methylcellulose.
  • the mixture (e.g., the dispersion (e.g., the spray dried dispersion)) comprises about 35% (w/w), about 40% (w/w), about 45% (w/w), about 50% (w/w), about 51% (w/w), about 52% (w/w), about 53% (w/w), about 54% (w/w), about 55% (w/w), about 56% (w/w), about 57% (w/w), about 58% (w/w), about 59% (w/w), about 60% (w/w), about 65% (w/w), about 70% (w/w), or about 75% (w/w) of hydroxypropyl methylcellulose.
  • the mixture (e.g., the dispersion (e.g., the spray dried dispersion)) comprises about 10% (w/w) to about 40% (w/w) of hydroxypropyl methylcellulose. In embodiments, the mixture (e.g., the dispersion (e.g., the spray dried dispersion)) comprises about 15% (w/w) to about 35% (w/w) of hydroxypropyl methylcellulose. In embodiments, the mixture (e.g., the dispersion (e.g., the spray dried dispersion)) comprises about 20% (w/w) to about 30% (w/w) of hydroxypropyl methylcellulose.
  • the mixture (e.g., the dispersion (e.g., the spray dried dispersion)) comprises 10% (w/w) to 40% (w/w) of hydroxypropyl methylcellulose. In embodiments, the mixture (e.g., the dispersion (e.g., the spray dried dispersion)) comprises 15% (w/w) to 35% (w/w) of hydroxypropyl methylcellulose. In embodiments, the mixture (e.g., the dispersion (e.g., the spray dried dispersion)) comprises 20% (w/w) to 30 % (w/w) of hydroxypropyl methylcellulose.
  • the mixture (e.g., the dispersion (e.g., a spray dried dispersion)) comprises about 10% (w/w), about 15% (w/w), about 20% (w/w), about 21% (w/w), about 22% (w/w), about 23% (w/w), about 24% (w/w), about 25% (w/w), about 26% (w/w), about 27% (w/w), about 28% (w/w), about 29% (w/w), about 30% (w/w), about 35% (w/w), or about 40% (w/w) of hydroxypropyl methylcellulose.
  • the mixture (e.g., the dispersion (e.g., a spray dried dispersion)) comprises about 1% (w/w) to about 10% (w/w) of a surfactant. In embodiments, the mixture comprises about 3% (w/w) to about 8% (w/w) of a surfactant. In embodiments, the mixture comprises about 4% (w/w) to about 6% (w/w) of a surfactant. In embodiments, the mixture comprises from 1% (w/w) to 10% (w/w) of a surfactant. In embodiments, the mixture comprises from 3% (w/w) to 8% (w/w) of a surfactant. In embodiments, the mixture comprises from 4% (w/w) to 6% (w/w) of a surfactant.
  • the mixture e.g., the dispersion (e.g., a spray dried dispersion)
  • the dispersion comprises about 1% (w/w), about 2% (w/w), about 3% (w/w), about 4% (w/w), about 5% (w/w), about 6% (w/w), about 7% (w/w), about 8% (w/w), about 9% (w/w), or about 10% (w/w) of a surfactant.
  • the mixture comprises about 1% (w/w) to about 10% (w/w) of D-a-tocopheryl polyethylene glycol succinate. In embodiments, the mixture comprises about 3% (w/w) to about 8% (w/w) of D-a-tocopheryl polyethylene glycol succinate. In embodiments, the mixture comprises about 4% (w/w) to about 6% (w/w) of D-a-tocopheryl polyethylene glycol succinate. In embodiments, the mixture comprises from 1% (w/w) to 10% (w/w) of D-a-tocopheryl polyethylene glycol succinate.
  • the mixture comprises from 3% (w/w) to 8% (w/w) of D-a-tocopheryl polyethylene glycol succinate. In embodiments, the mixture comprises from 4% (w/w) to 6% (w/w) of D-a-tocopheryl polyethylene glycol succinate.
  • the mixture e.g., the dispersion (e.g, the spray dried dispersion)
  • the dispersion comprises about 1% (w/w), about 2% (w/w), about 3% (w/w), about 4% (w/w), about 5% (w/w), about 6% (w/w), about 7% (w/w), about 8% (w/w), about 9% (w/w), or about 10% (w/w) of D-a- tocopheryl polyethylene glycol succinate.
  • the mixture e.g., the dispersion (e.g., the spray dried dispersion)
  • the dispersion comprises: about 20% (w/w) to about 60% (w/w) of Compound A, about 35% (w/w) to about 75% (w/w) of a polymer, and about 1% (w/w) to about 10% (w/w) of a surfactant.
  • the mixture (e.g., the dispersion (e.g., the spray dried dispersion)) comprises: about 40% (w/w) of Compound A, about 55% (w/w) of a polymer, and about 5% (w/w) of a surfactant.
  • the mixture (e.g., the dispersion (e.g., the spray dried dispersion)) comprises: about 50% to about 90% (w/w) of Compound A, about 10% to about 40% (w/w) of a polymer, and about 1% to about 10% (w/w) of a surfactant.
  • the mixture (e.g., the dispersion (e.g., the spray dried dispersion)) comprises: about 70% (w/w) Compound A, about 25% (w/w) of a polymer, and about 5% (w/w) of a surfactant.
  • the mixture e.g., the dispersion (e.g, the spray dried dispersion)
  • the dispersion comprises: about 20% (w/w) to about 60% (w/w) of Compound A, about 35% (w/w) to about 75% (w/w) of hydroxypropyl methylcellulose, and about 1% (w/w) to about 10% (w/w) of D-a-tocopheryl polyethylene glycol succinate.
  • the mixture (e.g., the dispersion (e.g., the spray dried dispersion)) comprises: about 40% (w/w) of Compound A, about 55% (w/w) of hydroxypropyl methylcellulose, and about 5% (w/w) of D-a-tocopheryl polyethylene glycol succinate.
  • the mixture (e.g., the dispersion (e.g., the spray dried dispersion)) comprises: about 50% to about 90% (w/w) of Compound A, about 10% to about 40% (w/w) of hydroxypropyl methylcellulose, and about 1% to about 10% (w/w) of D-a-tocopheryl polyethylene glycol succinate.
  • the mixture (e.g., the dispersion (e.g., the spray dried dispersion)) comprises: about 70% (w/w) Compound A, about 25% (w/w) hydroxypropyl methylcellulose, and about 5% (w/w) D-a-tocopheryl polyethylene glycol succinate.
  • the mixture (e.g., the dispersion (e.g., the spray dried dispersion)) comprises an amorphous form of Compound A.
  • the mixture (e.g., the spray dried dispersion) comprises a dispersion of amorphous Compound A, hydroxypropyl methylcellulose, and d-a- tocopheryl polyethylene glycol succinate.
  • the mixture of Compound A is in the form of a dispersion.
  • the dispersion is a solid dispersion.
  • the dispersion is produced by spray drying, lyophilization, hot melt extrusion, milling, solvent evaporation, supercritical fluid processing, or high-shear mixing.
  • the dispersion is produced by spray drying.
  • the dispersion (e.g., the spray dried dispersion) comprises Compound A, a polymer, and a surfactant.
  • the dispersion (e.g., the spray dried dispersion) comprises Compound A, D-a-tocopheryl polyethylene glycol succinate, and hydroxypropyl methylcellulose.
  • disclosed herein is a method of making the dispersion (e.g., a spray dried dispersion) comprising Compound A disclosed herein.
  • the method comprises:
  • the solvent may be a single organic solvent or a mixture of organic solvents.
  • the solvent is dichloromethane, methanol, or a combination thereof.
  • the solvent is dichloromethane.
  • the solvent is methanol.
  • the solvent is a mixture of dichloromethane and methanol.
  • the ratio of dichloromethane and methanol is about 90: 10 (w/w) to about 10:90 (w/w).
  • the ratio of dichloromethane and methanol is about 90:10 (w/w) to about 50:50 (w/w).
  • the ratio of dichloromethane and methanol is about 90:10 (w/w) to about 70:30 (w/w). In embodiments, the ratio of dichloromethane and methanol is about 85: 15 (w/w) to about 75:25 (w/w). In embodiments, the ratio of dichloromethane and methanol is 90: 10 (w/w) to
  • the ratio of dichloromethane and methanol is 85: 15 (w/w) to
  • the ratio of dichloromethane and methanol is 70:30 (w/w), about
  • the step of removing residual solvent is accomplished by drying.
  • the drying is accomplished by convection drying, tray drying, filter drying, tumble drying, agitated conical drying, or fluid bed drying.
  • the drying is accomplished by agitated conical drying.
  • the dosage form of Compound A is a solid oral dosage form.
  • the solid oral dosage form is a tablet, a sachet, or a capsule.
  • the solid oral dosage form is a tablet.
  • Suitable forms for oral administration may include one or more pharmaceutically acceptable excipients, including, for example, carriers, fillers, surfactants, diluents, sweeteners, disintegrants, binders, lubricants, glidants, colorants, flavors, stabilizing agents, coatings, or any mixtures thereof.
  • pharmaceutically acceptable excipients including, for example, carriers, fillers, surfactants, diluents, sweeteners, disintegrants, binders, lubricants, glidants, colorants, flavors, stabilizing agents, coatings, or any mixtures thereof.
  • Carriers include, but are not limited to, pharmaceutically acceptable excipients and diluents and means a material, composition, or vehicle, such as a liquid or solid filler, diluent, excipient, solvent, or encapsulating material, involved in carrying or transporting a pharmaceutical agent from one organ, or portion of the body, to another organ, or portion of the body of a subject.
  • examples include, but are not limited to, calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, and polymers such as polyethylene glycols.
  • Fillers include, but are not limited to, mannitol, sucrose, sorbitol, xylitol, microcrystalline cellulose, lactose, silicic acid, silicified microcrystalline cellulose, hydroxypropyl methylcellulose, hydroxypropyl cellulose, starch, pullulan, and fast dissolving carbohydrates such as PharmaburstTM fast disintegrating tablets, mixtures thereof, and the like.
  • fast-dissolving carbohydrates see, e.g., U.S. Patent No. 8,617,588, which is incorporated herein its entirety by reference.
  • Surfactants include, but are not limited to, non-ionic, anionic, cationic, amphoteric or zwitterionic surfactants.
  • suitable non-ionic surfactants include ethoxylated triglycerides; fatty alcohol ethoxylates; alkylphenol ethoxylates; fatty acid ethoxylates; fatty amide ethoxylates; fatty amine ethoxylates; sorbitan alkanoates; ethylated sorbitan alkanoates; alkyl ethoxylates; PluronicsTM; alkyl polyglucosides; stearol ethoxylates; alkyl polyglycosides.
  • anionic surfactants include alkylether sulfates; alkylether carboxylates; alkyl benzene sulfonates; alkylether phosphates; dialkyl sulfosuccinates; sarcosinates; alkyl sulfonates; soaps; alkyl sulfates; alkyl carboxylates; alkyl phosphates; paraffin sulfonates; secondary n-alkane sulfonates; alpha-olefin sulfonates; isethionate sulfonates.
  • Suitable cationic surfactants include fatty amine salts; fatty diamine salts; quaternary ammonium compounds; phosphonium surfactants; sulfonium surfactants; sulfoxonium surfactants.
  • suitable zwitterionic surfactants include N-alkyl derivatives of amino acids (such as glycine, betaine, aminopropionic acid); imidazoline surfactants; amine oxides; amidobetaines.
  • Nonlimiting examples of a surfactant that may be used in the ospemifene solid dispersions include, for example.
  • Tween 20 Tween 80, Span 20, Span 80, sodium docusate (e.g., AOT), sodium lauryl sulfate, and poloxamers (e.g., poloxamer 407, Kolliphor® EL, Pluronic F68). Poloxamers are also known by the trade names Synperonics®, Pluronics®, and Kolliphor®/Cremophor®.
  • Diluents include, but are not limited to, carbohydrates such as monosaccharides like glucose, oligosaccharides like sucrose and lactose (including anhydrous lactose and lactose monohydrate), starch such as maize starch, potato starch, rice starch and wheat starch, pregelatinized starch, calcium hydrogen phosphate, and sugar alcohols like sorbitol, mannitol, erythritol, and xylitol.
  • carbohydrates such as monosaccharides like glucose, oligosaccharides like sucrose and lactose (including anhydrous lactose and lactose monohydrate)
  • starch such as maize starch, potato starch, rice starch and wheat starch, pregelatinized starch, calcium hydrogen phosphate, and sugar alcohols like sorbitol, mannitol, erythritol, and xylitol.
  • Sweeteners include, but are not limited to, sucrose, high fructose corn syrup, fructose, glucose, aspartame, acesulfame K, sucralose, cyclamate, sodium saccharin, neotame, rebaudioside A, and other stevia-based sweeteners.
  • Disintegrants include, but are not limited to, sodium starch glycolate, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, croscarmellose sodium, crospovidone, chitosan, agar, alginic acid, calcium alginate, methyl cellulose, microcrystalline cellulose, powdered cellulose, lower alkylsubstituted hydroxypropyl cellulose, hydroxylpropyl starch, low-substituted hydroxypropylcellulose, polacrilin potassium, starch, pregelatinized starch, sodium alginate, magnesium aluminum silicate, polacrilin potassium, povidone, sodium starch glycolate, mixtures thereof, and the like.
  • Binders include, but are not limited to, hydroxypropylmethylcellulose (HPMC), hydroxypropyl cellulose (HPC), povidone, Copovidone, methylcellulose, powdered acacia, gelatin, gum arabicum, guar gum, carbomer such as carbopol, and polymethacrylates.
  • HPMC hydroxypropylmethylcellulose
  • HPC hydroxypropyl cellulose
  • HPC hydroxypropyl cellulose
  • HPC hydroxypropyl cellulose
  • HPC hydroxypropyl cellulose
  • HPC hydroxypropyl cellulose
  • povidone povidone
  • Copovidone methylcellulose
  • powdered acacia gelatin
  • gelatin gum arabicum
  • guar gum guar gum
  • carbomer such as carbopol
  • polymethacrylates include, but are not limited to, hydroxypropylmethylcellulose (HPMC), hydroxypropyl cellulose (HPC), povidone, Copovidone, methylcellulose
  • Lubricants include, but are not limited to, calcium stearate, glyceryl monostearate, glyceryl behenate, glyceryl palmitostearate, hexagonal boron nitride, hydrogenated vegetable oil, light mineral oil, magnesium stearate, mineral oil, polyethylene glycol, poloxamer, sodium benzoate, sodium lauryl sulfate, sodium stearyl fumarate, stearic acid, talc, zinc stearate, mixtures thereof, and the like.
  • Glidants include, but are not limited to, silicon dioxide, colloidal silicon dioxide, calcium silicate, magnesium silicate, magnesium trisilicate, talc, starch, mixtures thereof, and the like.
  • Flavors include, but are not limited to, menthol, peppermint oil, peppermint spirit, vanillin, and almond oil.
  • the amount of Compound A in the solid oral dosage form is about 5 mg to about 1000 mg. In embodiments, the amount of Compound A in the solid oral dosage form (e.g., the tablet) is about 5 mg to about 500 mg. In embodiments, the amount of Compound A in the solid oral dosage form (e.g., the tablet) is about 5 mg to about 250 mg. In embodiments, the amount of Compound A in the solid oral dosage form (e.g., the tablet) is about 25 mg to about 250 mg. In embodiments, the amount of Compound A in the solid oral dosage form (e.g., the tablet) is about 25 mg to about 200 mg.
  • the amount of Compound A in the solid oral dosage form is about 25 mg to about 150 mg. In embodiments, the amount of Compound A in the solid oral dosage form (e.g., the tablet) is about 50 mg to about 150 mg. In embodiments, the amount of Compound A in the solid oral dosage form (e.g., the tablet) is about 75 mg to about 125 mg. In embodiments, the amount of Compound A in the solid oral dosage form (e.g., the tablet) is about 5 mg to about 50 mg. In embodiments, the amount of Compound A in the solid oral dosage form (e.g., the tablet) is about 30 mg to about 40 mg.
  • the amount of Compound A in the solid oral dosage form is about 65 mg to about 70 mg. In embodiments, the amount of Compound A in the solid oral dosage form (e.g., the tablet) is about 100 mg to about 110 mg. In embodiments, the amount of Compound A in the solid oral dosage form (e.g., the tablet) is about 135 mg to about 145 mg. In embodiments, the amount of Compound A in the solid oral dosage form (e.g., the tablet) is from about 75 mg to about 300 mg. In embodiments, the amount of Compound A in the solid oral dosage form (e.g., the tablet) is from about 100 mg to about 300 mg. In embodiments, the amount of Compound A in the solid oral dosage form (e.g, the tablet) is from about 100 mg to about 250 mg.
  • the amount of Compound A in the solid oral dosage form is about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg, about 75 mg, about 80 mg, about 85 mg, about 90 mg, about 95 mg, about 100 mg, about 105 mg, about 110 mg, about 115 mg, about 120 mg, about 125 mg, about 130 mg, about 135 mg, about 140 mg, about 145 mg, about 150 mg, about 155 mg, about 160 mg, about 165 mg, about 170, about 175 mg, about 180 mg, about 185 mg, about 190 mg, about 195 mg, about 200 mg, about 205 mg, about 210 mg, about 215 mg, about 220 mg, about 225 mg, about 230 mg, about 235 mg, about 240 mg, about 245 mg, about 250 mg, about 255 mg, about 260 mg,
  • the solid oral dosage form (e.g., the tablet) comprises about 0.1% w/w, about 0.2% w/w, about 0.3% w/w, about 0.4% w/w, about 0.5% w/w, about 0.6% w/w, about 0.7% w/w, about 0.8% w/w, about 0.9% w/w, about 1.0% w/w, about 1.1% w/w, about 1.2% w/w, about 1.3% w/w, about 1.4% w/w, about 1.5% w/w, about 1.6% w/w, about 1.7% w/w.
  • the solid oral dosage form (e.g., the tablet) comprises about 1% w/w to about 5% w/w of Compound A, about 2.5% w/w to about 7.5% w/w of Compound A, about 10% w/w to about 15% w/w of Compound A, about 12.5% w/w to about 17.5% w/w of Compound A, about 15% w/w to about 20% w/w of Compound A, about 17.5% w/w to about 22.5% w/w of Compound A, about 20% w/w to about 25% w/w of Compound A, about 22.5% w/w to about 27.5% w/w of Compound A, about 25% w/w to about 30% w/w of Compound A, about 27.5% w/w to about 32.5% w/w of Compound A, about 30% w/w to about 35% w/w of Compound A, about 32.5% w/w to about 37.5% w/w of Compound A, about
  • the solid oral dosage form (e.g., the tablet) comprises from 1% w/w to 5% w/w of Compound A, from 2.5% w/w to 7.5% w/w of Compound A, from 10 % to 15 % w/w of Compound A, from 12.5% w/w to 17.5% w/w of Compound A, from 15% w/w to 20% w/w of Compound A, from 17.5% w/w to 22.5% w/w of Compound A, from 20% w/w to 25% w/w of Compound A, from 22.5% w/w to 27.5% w/w of Compound A, from 25% w/w to 30% w/w of Compound A, from 27.5% w/w to 32.5% w/w of Compound A, from 30% w/w to 35% w/w of Compound A, from 32.5% w/w to 37.5% w/w of Compound A, from 35% w/w to 40%
  • the solid oral dosage form (e.g., the tablet) comprises about 40% w/w to about 70% w/w of a mixture (e.g., a solid dispersion) disclosed herein. In embodiments, the solid oral dosage form (e.g., the tablet) comprises about 40% w/w to about 60% w/w of a mixture (e.g., a solid dispersion) disclosed herein. In embodiments, the solid oral dosage form (e.g., the tablet) comprises about 45% w/w to about 55% w/w of a mixture (e.g., a solid dispersion) disclosed herein. In embodiments, the solid oral dosage form (e.g., the tablet) comprises about 55% w/w to about 65% w/w of a mixture (e.g., a solid dispersion) disclosed herein.
  • a mixture e.g., a solid dispersion
  • the solid oral dosage form (e.g., the tablet) comprises 40% w/w to 70% w/w of a mixture (e.g., a solid dispersion) disclosed herein.
  • the solid oral dosage form (e.g., the tablet) comprises 40% w/w to 60% w/w of a mixture (e.g., a solid dispersion) disclosed herein.
  • the solid oral dosage form (e.g., the tablet) comprises 45% w/w to 55% w/w of a mixture (e.g., a solid dispersion) disclosed herein.
  • the solid oral dosage form (e.g., the tablet) comprises 55% w/w to 65% w/w of a mixture (e.g., a solid dispersion) disclosed herein.
  • the solid oral dosage form (e.g., the tablet) comprises: about 40% to about 60% w/w of a mixture (e.g., a solid dispersion) disclosed herein; about 10% to about 40% w/w of microcrystalline cellulose; about 5% to about 15% w/w of lactose monohydrate; about 5% to about 15% w/w of croscarmellose sodium; about 0% to about 5% w/w of silicon dioxide; and about 0% to about 2 % w/w of sodium stearyl fumarate.
  • a mixture e.g., a solid dispersion
  • the solid oral dosage form comprises: about 40% to about 60% w/w of a mixture (e.g., a solid dispersion) disclosed herein; about 10% to about 40% w/w of microcrystalline cellulose; about 5% to about 15% w/w of lactose monohydrate; about 5% to about 15% w/w of croscarmellose sodium; about 0% to about 5% w/
  • the solid oral dosage form (e.g., the tablet) comprises:
  • the solid oral dosage form (e.g., the tablet) comprises: about 40% to about 70% w/w of a mixture (e.g., a solid dispersion) disclosed herein about 10% to about 40% w/w of microcrystalline cellulose; about 5% to about 15% w/w of lactose monohydrate; about 5% to about 15% w/w of croscarmellose sodium; about 0% to about 5% w/w of silicon dioxide; and about 0% to about 2% w/w of sodium stearyl fumarate.
  • a mixture e.g., a solid dispersion
  • the solid oral dosage form (e.g., the tablet) comprises:
  • the solid oral dosage form (e.g., the tablet) comprises: about 45% to about 55% w/w of a mixture (e.g., a solid dispersion) disclosed herein (e.g., a mixture (e.g., a solid dispersion) comprising Compound A/HPMC/TPGS in a ratio of about 40:55:5 (w/w)); about 10% to about 40% w/w of microcrystalline cellulose; about 5% to about 15% w/w of lactose monohydrate; about 5% to about 15% w/w of croscarmellose sodium; about 0% to about 5% w/w of silicon dioxide; and about 0% to about 2% w/w of sodium stearyl fumarate.
  • a mixture e.g., a solid dispersion
  • Compound A/HPMC/TPGS in a ratio of about 40:55:5 (w/w)
  • about 10% to about 40% w/w of microcrystalline cellulose about 5% to about 15% w
  • the solid oral dosage form (e.g., the tablet) comprises:
  • a mixture e.g., a solid dispersion
  • a mixture e.g., a solid dispersion
  • Compound A/HPMC/TPGS in a ratio of about 40:55:5 (w/w)
  • the solid oral dosage form (e.g., the tablet) comprises: about 55% to about 65% w/w of a mixture (e.g., a solid dispersion) disclosed herein (e.g., a mixture (e.g., a solid dispersion) comprising Compound A/HPMC/TPGS in a ratio of about 70:25:5 (w/w)); about 10% to about 40% w/w of microcrystalline cellulose; about 5% to about 15% w/w of lactose monohydrate; about 5% to about 15% w/w of croscarmellose sodium; about 0% to about 5% w/w of silicon dioxide; and about 0% to about 2% w/w of sodium stearyl fumarate.
  • a mixture e.g., a solid dispersion
  • Compound A/HPMC/TPGS in a ratio of about 70:25:5 (w/w)
  • about 10% to about 40% w/w of microcrystalline cellulose about 5% to about 15% w
  • the solid oral dosage form (e.g., the tablet) comprises:
  • a mixture e.g., the solid dispersion disclosed herein (e.g., a mixture or dispersion comprising about 70% Compound A by weight, preferably a mixture (e.g., a solid dispersion) comprising Compound A/HPMC/TPGS in a ratio of about 70:25:5 (w/w));
  • the solid oral dosage form (e.g, the tablet) comprises: about 50% w/w of a mixture (e.g., the solid dispersion) disclosed herein (e.g., a mixture (e.g., a solid dispersion) comprising about 70% Compound A by weight, preferably a mixture (e.g., a solid dispersion) comprising Compound A/HPMC/TPGS in a ratio of about 40:55:5 (w/w)); about 27% w/w of microcrystalline cellulose; about 9% w/w of lactose monohydrate; about 12% w/w of croscarmellose sodium; about 1% w/w of silicon dioxide; and about 1.5% w/w of sodium stearyl fumarate.
  • a mixture e.g., the solid dispersion
  • a mixture e.g., a solid dispersion
  • Compound A/HPMC/TPGS in a ratio of about 40:55:5 (w/w)
  • the solid oral dosage form (e.g., the tablet) comprises: about 60% w/w of a mixture (e.g., the solid dispersion) disclosed herein (e.g., a mixture (e.g., a solid dispersion) comprising about 70% Compound A by weight, preferably a mixture (e.g., a solid dispersion) comprising Compound A/HPMC/TPGS in a ratio of about 70:25:5 (w/w)); about 17% w/w of microcrystalline cellulose; about 8.8% w/w of lactose monohydrate; about 12% w/w of croscarmellose sodium; about 1% w/w of silicon dioxide; and about 1.5% w/w sodium stearyl fumarate.
  • a mixture e.g., the solid dispersion
  • a mixture e.g., a solid dispersion
  • Compound A/HPMC/TPGS in a ratio of about 70:25:5 (w/w)
  • the solid oral dosage form (e.g., the tablet) comprises an intra-granular portion and an extra-granular portion, and, optionally, a film coating, wherein the intra-granular portion comprises: about 42% w/w of Compound A; about 14% w/w hydroxypropyl methylcellulose; about 3% w/w D-a-tocopheryl polyethylene glycol succinate; about 9% w/w microcrystalline cellulose; about 9% w/w lactose monohydrate; about 6% w/w croscarmellose sodium; about 1% w/w silicon dioxide; and about 0.75% w/w sodium stearyl fumarate, and wherein the extra- granular portion comprises: about 8% w/w microcrystalline cellulose; about 6% w/w croscarmellose sodium; and about 0.75% w/w sodium stearyl fumarate.
  • the intra-granular portion comprises: about 42% w/w of Compound A; about 14% w/w
  • the solid oral dosage form (e.g., the tablet) comprises an intra-granular portion and an extra-granular portion, and, optionally, a film coating, wherein the intra-granular portion comprises: about 40% to about 70% w/w of a mixture (e.g., a solid dispersion) as disclosed herein.
  • a mixture e.g., a solid dispersion
  • the solid oral dosage form (e.g., the tablet) comprises an intra-granular portion and an extra-granular portion, and, optionally, a film coating, wherein the intra-granular portion comprises:
  • microcrystalline cellulose 5% to 10% w/w of microcrystalline cellulose
  • croscarmellose sodium 1% to 10% w/w of croscarmellose sodium
  • the extra- granular portion comprises:
  • microcrystalline cellulose 5% to 25% w/w of microcrystalline cellulose
  • the solid oral dosage form (e.g., the tablet) comprises an intra-granular portion and an extra-granular portion, and, optionally, a film coating, wherein the intra-granular portion comprises: about 40% to about 60% w/w of a mixture (e.g., solid dispersion) as disclosed herein; about 5% to about 10% w/w of microcrystalline cellulose; about 5% to about 10% w/w of lactose monohydrate; about 1% to about 10% w/w of croscarmellose sodium; about 0% to about 5% w/w of silicon dioxide; and about 0% to about 2 % w/w of sodium stearyl fumarate, and wherein the extra-granular portion comprises about 5% to about 25% w/w of microcrystalline cellulose; about 0% to about 10 % w/w of croscarmellose sodium; and about 0% to about 2% w/w of sodium stearyl fumarate.
  • a mixture e.g., solid dispersion
  • the solid oral dosage form (e.g., the tablet) comprises an intra-granular portion and an extra-granular portion, and, optionally, a film coating, wherein the intra-granular portion comprises: 40% to 60% w/w of a mixture and/or solid dispersion as disclosed herein.
  • the solid oral dosage form (e.g., the tablet) comprises an intra-granular portion and an extra-granular portion, and, optionally, a film coating, wherein the intra-granular portion comprises: about 50% w/w of a mixture (e.g., a solid dispersion) as disclosed herein (e.g., a mixture (e.g., a solid dispersion) comprising about 70% Compound A by weight, preferably a mixture (e.g., a solid dispersion) comprising Compound A/HPMC/TPGS in a ratio of about 40:55:5 (w/w)); about 8% w/w microcrystalline cellulose; about 9% w/w lactose monohydrate; about 6% w/w croscarmellose sodium; about 1% w/w silicon dioxide; and about 0.75% w/w sodium stearyl fumarate, and wherein the extra-granular portion comprises about 18% w/w microcrystalline cellulose; about 6% w
  • the solid oral dosage form (e.g., the tablet) comprises an intra-granular portion and an extra-granular portion, and, optionally, a film coating, wherein the intra-granular portion comprises: about 60% w/w of a mixture (e.g., a solid dispersion) as disclosed herein (e.g., a mixture (e.g., a solid dispersion) comprising about 70% Compound A by weight, preferably a mixture (e.g., a solid dispersion) comprising Compound A/HPMC/TPGS in a ratio of about 70:25:5 (w/w)); about 9% w/w microcrystalline cellulose; about 9% w/w lactose monohydrate; about 6% w/w croscarmellose sodium; about 1% w/w silicon dioxide; and about 0.75% w/w sodium stearyl fumarate, and wherein the extra- granular portion comprises: about 8% w/w microcrystalline cellulose; about 6%
  • the solid oral dosage form (e.g., the tablet) comprises: about 15% w/w to about 50% w/w of Compound A; about 10% w/w to about 40% w/w of hydroxypropyl methylcellulose; about 0.5% w/w to about 5% w/w of D-a-tocopheryl polyethylene glycol succinate; about 10% w/w to about 40% w/w of microcrystalline cellulose; about 5% w/w to about 15% w/w of lactose monohydrate; about 5% w/w to about 15% w/w of croscarmellose sodium; about 0% w/w to about 5% w/w of silicon dioxide; and about 0% w/w to about 2% w/w of sodium stearyl fumarate.
  • the solid oral dosage form (e.g., the tablet) comprises:
  • the solid oral dosage form (e.g., the tablet) comprises: about 20% w/w of Compound A; about 28% w/w of hydroxypropyl methylcellulose; about 2.5% w/w of D-a-tocopheryl polyethylene glycol succinate; about 27% w/w of microcrystalline cellulose; about 9% w/w of lactose monohydrate; about 12% w/w of croscarmellose sodium; about 1% w/w of silicon dioxide; and about 1.5% w/w of sodium stearyl fumarate.
  • the solid oral dosage form (e.g., the tablet) comprises: about 42% w/w of Compound A; about 15% w/w of hydroxypropyl methylcellulose; about 3% w/w of D-a-tocopheryl polyethylene glycol succinate; about 17% w/w of microcrystalline cellulose; about 8.8% w/w of lactose monohydrate; about 12% w/w of croscarmellose sodium; about 1% w/w of silicon dioxide; and about 1.5% w/w of sodium stearyl fumarate.
  • the solid oral dosage form (e.g., the tablet) comprises an intra-granular portion and an extra-granular portion, and, optionally, a film coating, wherein the intra-granular portion comprises: about 15% to about 50% w/w of Compound A; about 10% to about 40% w/w of hydroxypropyl methylcellulose; about 0.5% to about 5% w/w of D-a-tocopheryl polyethylene glycol succinate; about 5% to about 10% w/w of microcrystalline cellulose; about 5% to about 10% w/w of lactose monohydrate; about 1% to about 10% w/w of croscarmellose sodium; about 0% to about 5% w/w of silicon dioxide; and about 0% to about 2% w/w of sodium stearyl fumarate, and wherein the extra- granular portion comprises: about 5% to about 25% w/w of microcrystalline cellulose; about 0% to about 10% w/w of croscarmellose sodium; and about 0% to
  • the solid oral dosage form (e.g., the tablet) comprises an intra-granular portion and an extra-granular portion, and, optionally, a film coating, wherein the intra-granular portion comprises: about 20% w/w of Compound A; about 28% w/w of hydroxypropyl methylcellulose; about 2.5% w/w of D-a-tocopheryl polyethylene glycol succinate; about 8% w/w of microcrystalline cellulose; about 9% w/w of lactose monohydrate; about 6% w/w of croscarmellose sodium; about 1% w/w of silicon dioxide; and about 0.75% w/w of sodium stearyl fumarate, and wherein the extra- granular portion comprises: about 18% w/w of microcrystalline cellulose; about 6% w/w of croscarmellose sodium; and about 0.75% w/w of sodium stearyl fumarate; wherein weight percentages are relative to the total uncoated tablet weight.
  • the solid oral dosage form (e.g., the tablet) comprises an intra-granular portion and an extra-granular portion, and optionally, a film coating
  • the intra-granular portion comprises: about 42% w/w of Compound A; about 14% w/w hydroxypropyl methylcellulose; about 3% w/w D-a-tocopheryl polyethylene glycol succinate; about 9% w/w microcrystalline cellulose; about 9% w/w lactose monohydrate; about 6% w/w croscarmellose sodium; about 1% w/w silicon dioxide; and about 0.75% w/w sodium stearyl fumarate; and wherein the extra- granular portion comprises: about 8% w/w microcrystalline cellulose; about 6% w/w croscarmellose sodium; and about 0.75% w/w sodium stearyl fumarate; wherein weight percentages are relative to the total uncoated tablet weight.
  • Solid formulations for oral administration may be formulated to be immediate and/or modified release.
  • Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted-, and programmed-release.
  • modified release formulations see U.S. Pat. No. 6,106,864.
  • Pharmaceuticals in the form of solid shaped tablets are typically manufactured by compressing the materials that make up the final product into the desired tablet form.
  • Such materials may include active pharmaceutical ingredients as well as pharmaceutically non-active excipients that impart necessary or useful properties to the product during and after the manufacturing process.
  • Tablet hardness, or tensile strength may be used as a measure of the cohesiveness of the ingredients of a tablet. If a tablet does not possess sufficient cohesive properties, the tablet may fall apart on handling.
  • the final formulation may comprise one or more layers and may be coated or uncoated.
  • granulation is a process used to improve the handling and manufacturing properties of a formulation, for example by increasing particle size to improve flow. Granulation does not substantially change the physical form of the drug such as its crystalline or amorphous character.
  • Various processes are used by those of skill in the art for preparing tablet dosage forms. Examples of such processes include dry-granulation, wet-granulation, fluid-bed granulation, and direct compression. The type of method used may depend upon factors such as physical characteristics of the active pharmaceutical ingredients in the formulation, the types of excipients used and the desired physical characteristics of the final product. Each of these processes include steps involving mixing of the ingredients of the dosage form.
  • roller compaction may be employed as a method to form the granules that are subsequently compressed into tablets. Roller compaction may reduce the subsequent compressibility and cohesiveness of the dosage form.
  • Dry granulation is a process in which granulates are formed by a compaction step that is followed by sizing the compacts into particles that may be processed easily. It is often used to improve flow properties and/or densify the formulation which may facilitate further manufacturing processes such as tableting, encapsulation and powder filling.
  • the compacts are made directly from powder blends that usually contain an active ingredient and other excipients including a lubricant.
  • dry granulation techniques may be preferred to wet granulation methods because of shorter processing times and cost advantages.
  • dry granulation is generally limited to those situations in which the drug or active ingredient has physical characteristics suitable for forming pharmaceutically acceptable granulations and dosage forms such as tablets.
  • excipient to the formulation is generally required and will contribute to increasing the tablet size of the final product.
  • tablet size must be within certain parameters to function as a suitable dosage form, there is a limit beyond which increasing tablet size to accommodate increasing amounts of excipients to enhance compatibility is not practical.
  • manufacturers are often limited to using the dry granulation method for formulations containing a low dose of the active ingredient per compressed tablet such that the formulation may accommodate sufficient levels of excipient to make dry granulation practical.
  • the dosage form should also optimally make available the active compound contained therein to the patient. Further, the dosage form should be easy to swallow. Smaller dosage forms may be better accepted by patients and may improve patient compliance.
  • the final pharmaceutical composition is processed into a unit dosage form (e.g., tablet or capsule) and then packaged for distribution.
  • a unit dosage form e.g., tablet or capsule
  • the processing step will vary depending upon the particular unit dosage form. For example, a tablet is generally compressed under pressure into a desired shape and a capsule employs a simple fill operation. Those skilled in the art are aware of the procedures used for manufacturing the various unit dosage forms.
  • Tablets are typically formed by pressure being applied to the material to be tableted on a tablet press.
  • a formulation must have good flow properties for precise volumetric feeding of the material to the die cavity and suitable compressibility, compatibility, and ejection properties to form a tablet.
  • Tablet presses There are several tablet presses, each varying in productivity but similar in basic function and operation. All compress a tablet formulation within a die cavity by pressure exerted between two steel punches, a lower punch, and an upper punch. Tablet presses are typically designed to have a hopper for holding and feeding the formulation, a feeding mechanism for feeding the formulation to the die cavity, provision for placement of punches and dies, and in rotary tablet presses a cam track for guiding the movement of the punches. Two types of tablet presses are the single station or single-punch press and the multistation rotary press. Some tablet presses provide longer dwell times than others, allowing increased bonding to occur. Other presses may provide precompression.
  • wet granulation methods may also be employed for preparing the granules of the pharmaceutical composition.
  • Wet granulation methods are described in Remington: The Science and Practice of Pharmacy, Mack Publishing Company, Easton, Pa., 19th Edition 1995. These and other methods are generally known by those skilled in the art.
  • a volatilizable agent may be incorporated in the mixture before, during or after mixing of the ingredients, but prior to formation of granules.
  • a solid volatilizable agent may be blended with the powders of the mixture prior to, during or after the addition of binding agent solutions.
  • Other solid dosage forms may be prepared using techniques including rotary bed granulation or spray- dried dispersion (SDD).
  • a film coating is provided around the solid oral dosage form (e.g., the tablet) of Compound A.
  • some or all the particles of the solid oral dosage form (e.g., the tablet) of Compound A are coated.
  • all weight percentages are relative to the total uncoated tablet weight.
  • the particles of the solid oral dosage form (e.g., the tablet) of Compound A are microencapsulated.
  • the particles of the solid oral dosage form (e.g., the tablet) of Compound A are not microencapsulated and are uncoated.
  • provided herein are methods for treating cancer in a subject comprising administering to the subject a solid oral dosage form comprising an effective amount of Compound A as described herein.
  • Solid oral dosage forms comprising Compound A may be administered alone or in combination with other drugs, in particular CDK4/6 inhibitors (e.g., dalpiciclib, trilaciclib, lerociclib, AT7519M, dinaciclib, riboci clib, abemaciclib, or palbociclib, or a pharmaceutically acceptable salt thereof).
  • CDK4/6 inhibitors e.g., dalpiciclib, trilaciclib, lerociclib, AT7519M, dinaciclib, riboci clib, abemaciclib, or palbociclib, or a pharmaceutically acceptable salt thereof.
  • locally advanced breast cancer is defined by the U.S. National Comprehensive Cancer Network as a subset of breast cancer characterized by the most advanced breast tumors in the absence of distant metastasis, wherein the tumors are more than 5 cm in size with regional lymphadenopathy; tumors of any size with direct extension to the chest wall or skin, or both (including ulcer or satellite nodules), regardless of regional lymphadenopathy; presence of regional lymphadenopathy (clinically fixed or matted axillary lymph nodes, or any of infraclavicular, supraclavicular, or internal mammary lymphadenopathy) regardless of tumor stage. (Garg et al. Curr Oncol. 2015 Oct; 22(5): e409-e410; National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Fort Washington, PA: NCCN; 2015. Ver. 2.2015.)
  • metastatic breast cancer refers to breast cancer that has spread beyond the breast and nearby lymph nodes to other parts of the body, e.g., bones, liver, lungs, brain.
  • CRPC castration resistant prostate cancer
  • ER+ estrogen receptor positive
  • HER2- human epidermal growth factor receptor 2 negative
  • HR hormone receptor
  • HER2+ human epidermal growth factor receptor 2 positive
  • NSCLC non-small cell lung cancer
  • PR progesterone receptor
  • the cancer is selected from lung cancer, mesothelioma, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, hepatic carcinoma, colon cancer, breast cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin’s disease, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, prostate cancer, hematology malignancy, chronic or acute leukemia, lymphocytic lymphomas, cancer of the bladder, cancer of the kidney or ureter, renal cell carcinoma, carcinoma of
  • the methods comprise treating cancer in a subject comprising administering to the subject a solid oral dosage form comprising an amount of Compound A, as described herein, that is effective in treating the cancer.
  • the cancer is breast, lung, colon, brain, head and neck, prostate, stomach, pancreatic, ovarian, melanoma, endocrine, uterine, testicular, or bladder.
  • the cancer is breast, lung, prostate, pancreatic, or ovarian.
  • the cancer is breast, lung, or prostate.
  • the cancer is breast cancer.
  • the breast cancer is metastatic breast cancer.
  • the breast cancer is locally advanced breast cancer.
  • the breast cancer is HR+ breast cancer.
  • the HR+ breast cancer is PR+ and/or ER+ breast cancer.
  • the breast cancer is PR+ breast cancer.
  • the breast cancer is ER+ breast cancer. In embodiments, the breast cancer is ER+ HER2- breast cancer.
  • the breast cancer is ER+ HER2+ breast cancer.
  • the breast cancer is locally advanced or metastatic ER+ breast cancer.
  • the breast cancer is locally advanced or metastatic ER+ HER2- breast cancer.
  • the breast cancer is locally advanced or metastatic ER+ HER2+ breast cancer.
  • the breast cancer is metastatic, ER+, HER2- breast cancer.
  • the breast cancer is metastatic, ER+, HER2- breast cancer that is also locally advanced.
  • the lung cancer is non-small cell lung cancer.
  • the lung cancer is locally advanced or metastatic non-small cell lung cancer.
  • the prostate cancer is CRPC.
  • the prostate cancer is locally advanced or metastatic CRPC.
  • methods of treating solid tumors in a subject comprising administering to the subject a solid oral dosage form, comprising an amount of Compound A, as described herein, that is effective in treating the solid tumor.
  • the solid tumor is breast, lung, colon, brain, head and neck, prostate, stomach, pancreatic, ovarian, melanoma, endocrine, uterine, testicular, or bladder.
  • the solid tumor is breast, lung, prostate, pancreatic, or ovarian.
  • the solid tumor is breast, lung, or prostate.
  • the solid tumor is breast cancer.
  • the breast cancer is HR+ breast cancer.
  • the HR+ breast cancer is PR+ and/or ER+ breast cancer ER+ breast cancer.
  • the solid tumor is breast cancer.
  • the breast cancer is ER+ HER2- breast cancer.
  • the solid tumor is breast cancer.
  • the breast cancer is ER+ HER2+ breast cancer.
  • the solid tumor is breast cancer.
  • the breast cancer is locally advanced or metastatic ER+ HER2- breast cancer.
  • the solid tumor is breast cancer.
  • the breast cancer is locally advanced or metastatic ER+ HER2+ breast cancer.
  • the solid tumor is lung cancer.
  • the lung cancer is non-small cell lung cancer.
  • the solid tumor is lung cancer.
  • the lung cancer is locally advanced or metastatic non-small cell lung cancer.
  • the solid tumor is prostate cancer.
  • the prostate cancer is CRPC.
  • the solid tumor is prostate cancer.
  • the prostate cancer is locally advanced or metastatic castration resistant prostate cancer.
  • the method comprises treating hematologic tumors in a subject comprising administering to the subject a solid oral dosage form comprising an amount of Compound A, as described herein, that is effective in treating the hematologic tumor.
  • the hematologic tumor is leukemia, lymphoma, or multiple myeloma.
  • the hematologic tumor is leukemia or lymphoma. Also disclosed herein are methods of treating cancer in a subject with locally advanced or metastatic ER+HER2- breast cancer, CRPC, or NSCLC whose disease progressed on or is intolerant to standard therapy.
  • Compound A 50 mg, 100 mg, 200 mg, and 250 mg tablets of Compound A were produced using two different formulations resulting in 20% and 42% Compound A drug load.
  • Compound A was prepared in the form of a spray dried solid dispersion (SDD), composed of Compound A/HPMC E3/Vitamin E TPGS in 70:25:5% w/w or 40:55:5% w/w ratio.
  • SDD spray dried solid dispersion
  • compositions of the 50 mg, 100 mg, 200 mg, and 250 mg tablets of Compound A as an SDD, composed of Compound A/HPMC E3/Vitamin E TPGS, and the composition of the 100 mg tablets of Compound A as an SDD, composed of 40:55:5% w/w ratio, are shown below in Table 2.
  • Materials used in preparation of the spray dried dispersions (SDDs) are shown below in Table 4.
  • Tables 1-4 are theoretical formulations for a single unit (the QQ formula (Qua Que)). When a pharmaceutical product is scaled up to multiple units, the quantity for each component is multiplied by the number of units required.
  • Table 2 Tablet Compositions for 100 mg Tablets.
  • Table 3 Tablet Compositions for 200 mg and 250 mg Tablets.
  • a stainless steel reactor was charged with dichloromethane and methanol under nitrogen atmosphere. The mixture was stirred with a low vortex (between 25 and 100 rpm) and the temperature was maintained at 2-8 °C (for the 70/25/5 Dispersion) or 15-25 °C (for the 40/55/5 Dispersion). Vitamin E TPGS was added and the solution was stirred until an absence of solids in suspension was achieved. Methocel (i.e., HPMC) was added and the solution was stirred until an absence of solids in suspension was achieved. The temperature was adjusted to between 15- 25 °C (for the 70/25/5 Dispersion) and the solution was stirred for at least 30 minutes until a clear solution was achieved.
  • Methocel i.e., HPMC
  • the jacket temperature was lowered to 20 °C and the product was allowed to cool to 40 °C.
  • the intra-granular materials were blended and compacted, mixed with the extra-granular excipients, and further blended.
  • the resulting granules were compressed into 120 mg, 240 mg, 480 mg, 500 mg, or 600 mg tablets.
  • the resulting tablet may be film-coated.
  • Fasted female dogs were orally administered Compound A (7.5 mg/kg), as spray-dried dispersions (SDDs), pure amorphous API, or crystalline API, in aqueous suspension containing 0.5% Methocel A4M at 2 mL/kg.
  • Animals were pretreated with famotidine at 0.5 mg/kg IV 1 hour before administration of Compound A to raise gastric pH.
  • pentagastrin (6 pg/kg intramuscularly 1 hour before administration of crystalline Compound A as a low gastric pH comparator.
  • API active pharmaceutical ingredient
  • HPMC E3LV low viscosity E3 -grade hydroxypropyl methylcellulose
  • HPMCAS-L L-grade hydroxypropyl methylcellulose acetate succinate
  • SDD spray-dried dispersion
  • VitE TPGS D-a-tocopheryl polyethylene glycol 1000 succinate
  • wt weight.
  • prototype 50 mg strength Compound A tablets were made at laboratory scale using the Compound A: low viscosity E3-grade hydroxypropyl methylcellulose (HPMC E3LV):Vitamin E TPGS (40:55:5) dispersion and crystalline drug substance (with and without an acidulant - fumaric acid) having the compositions shown in Table 8.
  • Acidulant fluumaric acid
  • Table 8 Compositions of 50 mg Compound A Tablet Prototypes
  • D50 size below which 50% of the material volume is present;
  • HPMC E3LV low viscosity E3 -grade hydroxypropyl methylcellulose;
  • SDD spray-dried dispersion;
  • VitE TPGS D-a-tocopheryl polyethylene glycol 1000 succinate.
  • Female dogs were pretreated with famotidine at 0.5 mg/kg IV 1 hour before administration of a single 50 mg Compound A tablet. Study animals were either fasted (subsequently fed 4 hours after Compound A administration) or fed (0.5 hours before dosing)
  • results in fasted study animals show that exposure of size-reduced API was slightly improved by microenvironmental acidification (using fumaric acid) - see comparison of FIGs 2B vs 2D. It was also noted that increased particle size does not affect exposure in the presence of acid - see comparison of FIGs 2C vs 2D.
  • the spray-dried dispersion in HPMC and TPGS provided the best exposure.
  • Results in fed study animals, shown in FIGs 3A-3D showed an approximately three-fold increase in exposure for all formulations compared to fasted subjects. As with fasted subjects, the spray-dried dispersion in HPMC and TPGS provided the best exposure.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Sont divulgués des formes posologiques orales solides comprenant le composé A, ou un sel pharmaceutiquement acceptable de celui-ci.
PCT/US2024/033417 2023-06-12 2024-06-11 Formes posologiques orales solides d'agents de dégradation des récepteurs des œstrogènes Pending WO2024258856A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
KR1020267000497A KR20260022394A (ko) 2023-06-12 2024-06-11 에스트로겐 수용체 분해제의 고형 경구제
CN202480038499.7A CN121311218A (zh) 2023-06-12 2024-06-11 雌激素受体降解剂的固体口服剂型
AU2024303588A AU2024303588A1 (en) 2023-06-12 2024-06-11 Solid oral dosage forms of estrogen receptor degraders
IL325099A IL325099A (en) 2023-06-12 2025-12-03 Oral solid estrogen receptor antagonist dosage forms
MX2025014795A MX2025014795A (es) 2023-06-12 2025-12-08 Formas farmaceuticas orales solidas de degradadores de receptores de estrogeno

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363472523P 2023-06-12 2023-06-12
US63/472,523 2023-06-12

Publications (1)

Publication Number Publication Date
WO2024258856A1 true WO2024258856A1 (fr) 2024-12-19

Family

ID=91738206

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/033417 Pending WO2024258856A1 (fr) 2023-06-12 2024-06-11 Formes posologiques orales solides d'agents de dégradation des récepteurs des œstrogènes

Country Status (7)

Country Link
KR (1) KR20260022394A (fr)
CN (1) CN121311218A (fr)
AU (1) AU2024303588A1 (fr)
IL (1) IL325099A (fr)
MX (1) MX2025014795A (fr)
TW (1) TW202500155A (fr)
WO (1) WO2024258856A1 (fr)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6106864A (en) 1995-09-15 2000-08-22 Pfizer Inc. Pharmaceutical formulations containing darifenacin
US8617588B2 (en) 2009-03-09 2013-12-31 Spi Pharma, Inc. Highly compactable and durable direct compression excipients and excipient systems
WO2016193860A1 (fr) * 2015-06-04 2016-12-08 Pfizer Inc. Formes galéniques solides de palbociclib
WO2018102725A1 (fr) 2016-12-01 2018-06-07 Arvinas, Inc. Dérivés de tétrahydronaphtalène et de tétrahydroisoquinoléine en tant qu'agents de dégradation des récepteurs des œstrogènes
WO2021041348A1 (fr) 2019-08-26 2021-03-04 Arvinas Operations, Inc. Procédés de traitement du cancer du sein avec des dérivés de tétrahydronaphtalène en tant qu'agents de dégradation du récepteur des œstrogènes
WO2022056368A1 (fr) * 2020-09-14 2022-03-17 Arvinas Operations, Inc. Formes cristallines d'un composé pour la dégradation ciblée du récepteur des œstrogènes
WO2023179777A1 (fr) * 2022-03-25 2023-09-28 Shenzhen Pharmacin Co., Ltd. Compositions pharmaceutiques de composés protac et leurs utilisations

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6106864A (en) 1995-09-15 2000-08-22 Pfizer Inc. Pharmaceutical formulations containing darifenacin
US8617588B2 (en) 2009-03-09 2013-12-31 Spi Pharma, Inc. Highly compactable and durable direct compression excipients and excipient systems
WO2016193860A1 (fr) * 2015-06-04 2016-12-08 Pfizer Inc. Formes galéniques solides de palbociclib
WO2018102725A1 (fr) 2016-12-01 2018-06-07 Arvinas, Inc. Dérivés de tétrahydronaphtalène et de tétrahydroisoquinoléine en tant qu'agents de dégradation des récepteurs des œstrogènes
US10647698B2 (en) 2016-12-01 2020-05-12 Arvinas Operations, Inc. Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders
US10899742B1 (en) 2016-12-01 2021-01-26 Arvinas Operations, Inc. Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders
US11104666B2 (en) 2016-12-01 2021-08-31 Arvinas Operations, Inc. Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders
WO2021041348A1 (fr) 2019-08-26 2021-03-04 Arvinas Operations, Inc. Procédés de traitement du cancer du sein avec des dérivés de tétrahydronaphtalène en tant qu'agents de dégradation du récepteur des œstrogènes
WO2022056368A1 (fr) * 2020-09-14 2022-03-17 Arvinas Operations, Inc. Formes cristallines d'un composé pour la dégradation ciblée du récepteur des œstrogènes
WO2023179777A1 (fr) * 2022-03-25 2023-09-28 Shenzhen Pharmacin Co., Ltd. Compositions pharmaceutiques de composés protac et leurs utilisations

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
"Handbook of Pharmaceutical Salts: Properties, Selection, and Use by Stahl and Wermuth", 2002, WILEY-VCH
"Pharmacy", 1995, MACK PUBLISHING COMPANY
"Remingtons's Pharmaceutical Sciences", 2000
EMMANUEL ET AL., PHARMACEUTICS, vol. 2, 2010, pages 351 - 63
GARG ET AL., CURR ONCOL, vol. 22, no. 5, October 2015 (2015-10-01), pages e409 - e410
S. T. COLGANR. J. TIMPANOD. DIAZM. ROBERTSR. WEAVERK. RYANK. FIELDSG. SCRIVENS: "Opportunities for Lean Stability Strategies", J. PHARM. INNOV, vol. 9, 2014, pages 259 - 71
S. T. COLGANT. J. WATSONR. D. WHIPPLER. NOSALJ. V. BEAMAND. DE ANTONIS: "The Application of Science and Risk Based Concepts to Drug Substance Stability Strategies", J. PHARM. INNOV, vol. 7, 2012, pages 205 - 2013
WATERMAN K CCARELLA A JGUMKOWSKI M J ET AL.: "Improved protocol and data analysis for accelerated shelf-life estimation of solid dosage forms", PHARM RES, vol. 24, no. 4, 2007, pages 780 - 90, XP019483511, DOI: 10.1007/s11095-006-9201-4

Also Published As

Publication number Publication date
KR20260022394A (ko) 2026-02-19
IL325099A (en) 2026-02-01
AU2024303588A1 (en) 2025-12-18
MX2025014795A (es) 2026-01-07
CN121311218A (zh) 2026-01-09
TW202500155A (zh) 2025-01-01

Similar Documents

Publication Publication Date Title
AU2015214502B2 (en) Tablet formulation for CGRP-active compounds
KR20150097792A (ko) 개선된 생체이용률을 갖는 약학 조성물
US20110136883A1 (en) Granulation of active pharmaceutical ingredients
WO2012164578A1 (fr) Compositions et procédés de préparation de formulations de nilotinib à libération immédiate
US20120231076A1 (en) Pharmaceutical compositions comprising rivaroxaban
WO2015124995A1 (fr) Formes galéniques solides de rivaroxaban
JP7648698B2 (ja) 難溶性の塩基性薬剤を含有する医薬組成物
EP3620156A1 (fr) Composition ayant une solubilité dans l'eau et une biodisponibilité améliorées
WO2022013360A1 (fr) Composition pharmaceutique comprenant un ivacaftor
KR101479824B1 (ko) 용출 안정성 제제
US20140319720A1 (en) Pharmaceutical compositions comprising rivaroxaban
TWI624275B (zh) 具有高含量菲索芬那定（ｆｅｘｏｆｅｎａｄｉｎｅ）之固態單位及其製備方法
EP2291079B1 (fr) Préparations pour inhibiteurs de la cathepsine k
JP6630229B2 (ja) レベチラセタム含有医薬組成物及びその製造方法
NZ760233A (en) Compositions and methods for treatment of abnormal cell growth
JP5635491B2 (ja) 固形医薬組成物
US10709699B2 (en) Pyridone derivative pharmaceutical composition and preparation method thereof
US20160106679A1 (en) Tablet with increased drug load of odanacatib
WO2008118031A1 (fr) Composition pharmaceutique comprenant du candésartan cilexétil et procédé de fabrication
WO2024258856A1 (fr) Formes posologiques orales solides d'agents de dégradation des récepteurs des œstrogènes
US20090030057A1 (en) Pharmaceutical composition of telmisartan
WO2017093890A1 (fr) Formulation de comprimé à base de clobazam et son procédé de préparation
WO2011161689A1 (fr) Comprimé pharmaceutique de mésylate d'imatinib
US11260055B2 (en) Oral pharmaceutical composition of lurasidone and preparation thereof
KR101944085B1 (ko) 발사르탄 함유 고형 경구제형 및 그 제조방법

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24737275

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 325099

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: AU2024303588

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: MX/A/2025/014795

Country of ref document: MX

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112025026864

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2024303588

Country of ref document: AU

Date of ref document: 20240611

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 202593500

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 325099

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 1020267000497

Country of ref document: KR

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A15-NAP-PA0105 (AS PROVIDED BY THE NATIONAL OFFICE)

WWE Wipo information: entry into national phase

Ref document number: 1020267000497

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: MX/A/2025/014795

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2024737275

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2024737275

Country of ref document: EP

Effective date: 20260112

ENP Entry into the national phase

Ref document number: 2024737275

Country of ref document: EP

Effective date: 20260112

WWE Wipo information: entry into national phase

Ref document number: 11202508189P

Country of ref document: SG

WWP Wipo information: published in national office

Ref document number: 11202508189P

Country of ref document: SG

ENP Entry into the national phase

Ref document number: 2024737275

Country of ref document: EP

Effective date: 20260112

ENP Entry into the national phase

Ref document number: 2024737275

Country of ref document: EP

Effective date: 20260112

WWP Wipo information: published in national office

Ref document number: 1020267000497

Country of ref document: KR